Eli Lilly and Company (NYSE:LLY) Shares Bought by Mezzasalma Advisors LLC

Mezzasalma Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 110.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,243 shares of the company’s stock after acquiring an additional 3,275 shares during the quarter. Eli Lilly and Company accounts for about 2.3% of Mezzasalma Advisors LLC’s holdings, making the stock its 12th biggest position. Mezzasalma Advisors LLC’s holdings in Eli Lilly and Company were worth $4,857,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. FORVIS Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 38.6% during the 1st quarter. FORVIS Wealth Advisors LLC now owns 61,819 shares of the company’s stock worth $48,093,000 after buying an additional 17,222 shares during the last quarter. Everett Harris & Co. CA raised its stake in shares of Eli Lilly and Company by 0.5% during the 1st quarter. Everett Harris & Co. CA now owns 8,938 shares of the company’s stock worth $6,953,000 after buying an additional 45 shares during the last quarter. GenTrust LLC raised its stake in shares of Eli Lilly and Company by 75.3% during the 1st quarter. GenTrust LLC now owns 675 shares of the company’s stock worth $525,000 after buying an additional 290 shares during the last quarter. Willis Johnson & Associates Inc. raised its stake in shares of Eli Lilly and Company by 35.1% during the 1st quarter. Willis Johnson & Associates Inc. now owns 531 shares of the company’s stock worth $413,000 after buying an additional 138 shares during the last quarter. Finally, Whelan Financial acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth $297,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 858,742 shares of company stock worth $735,573,781. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday. Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Bank of America reissued a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a research note on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Trading Down 0.9 %

Shares of NYSE:LLY traded down $8.61 during trading on Thursday, reaching $898.10. 3,078,367 shares of the stock were exchanged, compared to its average volume of 2,667,176. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $918.50. The firm has a market cap of $853.56 billion, a price-to-earnings ratio of 132.27, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. The firm’s 50-day moving average price is $824.60 and its 200 day moving average price is $746.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the business earned $1.62 EPS. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.